Arsanis receives patent for ASN100.
Arsanis announced that the United States Patent and Trademark Office, or USPTO issued U.S. Patent No. 9914767 to the company. This patent broadly claims composition of matter for antibodies that cross-neutralize Staphylococcus aureus alpha hemolysin and up to four additional S. aureus leukocidins targeted by ASN-1, one of the two antibodies in the company's lead product candidate, ASN100. ASN100 is a combination of two fully human monoclonal antibodies that together neutralize the six cytotoxins critical to S. aureus pneumonia pathogenesis, including toxins that damage lung tissue and destroy human immune cells. This patent grants intellectual property protection in the United States through 2033.
|Printer friendly Cite/link Email Feedback|
|Date:||Mar 14, 2018|
|Previous Article:||NV5 Global announces $10M ccontract from CCTA.|
|Next Article:||Inovio says interim Phase 1 data of DNA immunotherapy meets objectives.|